Preemptive treatment of severe morning sickness decreases suffering for moms-to-be
2013-02-11
(Press-News.org) `In a study to be presented on February 14 between 1:15 p.m., and 3:30 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, California, researchers will present data showing the effectiveness of preemptive treatment for hyperemesis gravidarum and severe morning sickness.
Hyperemesis gravidarum is a severe form of morning sickness which effects one in 50 pregnant women. HG is marked by persistent nausea and vomiting, and can begin early in the first trimester, continuing well into the second, third or even up to giving birth. Women who suffer from HG become severely dehydrated, and often end up in the hospital on IV fluids. Twenty percent of women who had HG in their first pregnancy will experience it in subsequent pregnancies, and the condition can be fatal.
Previous treatment for HG was to administer medication (Diclectin in Canada, Bendectin in the US) at the onset of symptoms, but this course of treatment provided little, if any, relief.
Drs. Gideon Koren and Caroline Maltepe, of The Hospital for Sick Children in Toronto, ON, Canada, divided 59 women with a history of HG or severe morning sickness into two groups: one would begin taking Diclectin as soon as the pregnancy was discovered; the second group would begin treatment at the onset of HG symptoms.
They found the group receiving treatment before the onset of symptoms, had a significant decrease in risk of severe nausea and vomiting.
"This is the first time there is an answer," said Dr. Koren. "Women who have experienced hyperemesis are so traumatized by it, they are afraid of a second pregnancy."
Dr. Koren, who with Dr. Maltepe runs a severe morning sickness counseling program at The Hospital for Sick Children, says the drug used to treat HG is safe to take throughout pregnancy or even before conception.
### Koren and Maltepe conducted the study at The Hospital for Sick Children, The Motherisk Program/Division of Clinical Pharmacology and Toxicology, Toronto, ON, Canada.
A copy of the abstract is available at www.smfmnewsroom.org/annual-meeting/meeting-abstracts/ and below. For interviews please contact Vicki Bendure at Vicki@bendurepr.com, or 202-374-9259 (cell) ), or Meghan Blackburn at Meghan@bendurepr.com, 540-687-5099 (office) or 859-492-6303 (cell).
The Society for Maternal-Fetal Medicine (est. 1977) is a non-profit membership group for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine. The society is devoted to reducing high-risk pregnancy complications by providing continuing education to its 2,000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine. The group hosts an annual scientific meeting in which new ideas and research in the area of maternal-fetal medicine are unveiled and discussed. For more information, visit www.smfm.org or www.facebook.com/SocietyforMaternalFetalMedicine.
Abstract 31: Preemptive Diclectin therapy for the management of nausea and vomiting of pregnancy and hyperemesis gravidarum
Gideon Koren1, Caroline Maltepe1
1The Hospital for Sick Children, The Motherisk Program/Division of Clinical Pharmacology and Toxicology, Toronto, ON, Canada
OBJECTIVE: Our primary objective in this study was to determine whether the initiation of pre-emptive use of Diclectin (delayed release combination of 10 mg pyridoxine and 10 mg doxylamine) before symptoms of nausea and vomiting of pregnancy (NVP) began can mitigate symptoms as compared to starting Diclectin only at first sign of NVP symptoms, in patients with a high risk for recurrence of severe NVP or hyperemesis gravidarum (HG).
STUDY DESIGN: This study was a prospective, randomized controlled trial. Women with history of severe NVP and/or HG in their previous pregnancy were recruited to participate. Upon consent, patients were randomized to start taking Diclectin upon recognition of their pregnancy but before NVP symptoms began, or to start only upon appearance of symptoms. Both study groups received similar, intensive protocolized counseling as per evidence-based guidelines for NVP management.
RESULTS: A total of 30 women were randomized to the preemptive study group and 29 to the control study group. There was a 43.3% reduction in the recurrence of HG with pre-emptive use of Diclectin as compared to only 20.6% reduction in the control group (p < 0.05). There were 70% fewer cases of moderate-severe cases of NVP (PUQE ≥ 11) in the preemptive study group with Diclectin than in the control group (15.4% vs. 39.13%) in the first 3 weeks of NVP (p < 0.04). Significantly more women in the preemptive group (78.2%) had their NVP resolved before delivery compared to the control group (50%) (p < 0.002). The mean (SD) dose of Diclectin over the course of NVP was no different between the pre-emptive group 0.65 mg/kg/d (SD = 0.23) and the control group 0.56 mg/kg/d (0.24). Both study group patients received a mean of 8 follow-up calls (SD 1.8).
CONCLUSION: Preemptive use of Diclectin combined with intensive protocolized counseling effectively decreases the risk of severe forms of NVP.
ELSE PRESS RELEASES FROM THIS DATE:
2013-02-11
In a study to be presented on February 14 between 1:15 p.m., and 3:30 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, California, researchers will present data showing racial and ethnic disparities exist for adverse obstetric outcomes.
In his study Dr. William Grobman of Northwestern University, presenting for the Eunice Kennedy Shriver National Institute of Child Health and Human Development, studied 115,502 women over a three year period to see if adverse obstetric outcomes and provisions in obstetric ...
2013-02-11
In a study to be presented on February 15 between 8 a.m. and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, California, researchers from Tufts Medical Center will present findings showing the effects of maternal obesity on a fetus, specifically in the development of the brain.
The study, conducted at the Mother Infant Research Institute (MIRI) at Tufts Medical Center in Boston, Mass., looked at the fetal development of 16 pregnant women, eight obese and eight lean, to see what effects maternal obesity ...
2013-02-11
In a study to be presented on February 15 between 8 a.m., and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will report findings that women with obstructive sleep apnea (OSA) and cardiac symptoms have a 31 percent incidence of cardiac dysfunction. The use of echocardiograms should be considered in the clinical management of these women.
OSA is characterized by abnormal pauses in breathing or instances of abnormally low breathing, during sleep. These pauses can last from at least ten seconds ...
2013-02-11
PROVIDENCE, R.I. [Brown University] — Newly published results from a randomized controlled clinical trial in the Pacific U.S. territory of American Samoa add clear evidence for the emerging idea that community health workers can meaningfully improve type 2 diabetes care in medically underserved communities.
In the U.S. territory, 21.5 percent of adults have type 2 diabetes. Meanwhile, 58 percent of families are below the U.S. poverty level. The research team, led by public health researchers from Brown and The Miriam Hospital, wanted to test whether four trained local ...
2013-02-11
In a study to be presented on February 15 between 1:15 p.m., and 3:30 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will report findings that suggest that consistent physical activity and healthier lifestyle changes beginning in a woman's first trimester can prevent excessive weight gain in obese pregnant women (with a Body Mass Index greater than 30), helping to avoid preterm delivery, hypertension and gestational diabetes.
This randomized study, entitled Occurrence of pregnancy complications ...
2013-02-11
In a study to be presented on February 16 between 8 a.m., and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will report findings that suggest shifting from a traditional model of obstetrical care to a laborist model improves pregnancy outcomes.
The "laborist" concept has been around for nearly a decade. In this model, obstetricians provide 24-hour a day on-site staffing of labor units. While it has been assumed that laborists improve obstetric care, there had been no studies done to test ...
2013-02-11
In a study to be presented on February 16 between 8 a.m., and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will report findings that suggest around-the-clock labor and delivery coverage decreased the odds of cesarean delivery.
The objective of the study was to determine if the implementation of "laborists" to provide around-the-clock coverage of labor and delivery would produce better outcomes. The study compared outcomes in hospitals with around-the-clock coverage versus hospitals whose ...
2013-02-11
In a study to be presented on February 16 between 8 a.m., and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will report findings that suggest comprehensive maternal hemorrhage protocols reduce utilization of blood products and improve patient safety.
A study performed at Dignity Health, the fifth largest health care system in the United States with 31 obstetrical units, showed that the implementation of a standardized comprehensive maternal hemorrhage (CHP) protocol directed towards prevention ...
2013-02-11
In a study to be presented on February 16 between 8 a.m., and 10 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting ™, in San Francisco, researchers will report findings that suggest women whose babies are small-for-gestational-age (SGA) in their first pregnancy have a strongly increased risk for SGA in a second pregnancy.
The aim of this study was to assess and describe in detail the incidence of SGA infants and the SGA recurrence rate in general. Additionally, it sought to assess the incidence and recurrence rate of SGA in women ...
2013-02-11
New research from the University of Adelaide will rewrite the textbooks on how an ovary is formed, as well as providing new insights into women's health and fertility.
The study, now published in the journal PLOS ONE, also names a new type of cell that plays a key role in the development of ovaries and ovarian follicles, which are responsible for the production of eggs in women.
The discovery is expected to prompt further studies around the world to better understand how ovaries and ovarian follicles develop in female fetuses. This could be critical to treating or ...
LAST 30 PRESS RELEASES:
[Press-News.org] Preemptive treatment of severe morning sickness decreases suffering for moms-to-be
